Literature DB >> 7690415

Cofactor requirement for human immunodeficiency virus type 1 entry into a CD4-expressing human cell line.

R D Harrington1, A P Geballe.   

Abstract

Expression of the human immunodeficiency virus type 1 (HIV-1) receptor CD4 on many nonhuman and some human cell lines is not sufficient to permit HIV-1 infection. We describe a human glioblastoma cell line (U373-MG) which remains resistant to HIV-1 despite the added expression of an authentic CD4 molecule. The block to HIV-1 infection of these cells is strain independent and appears to be at viral entry. Heterokaryons of CD4-expressing U373-MG (U373-CD4) cells fused to HeLa cells allow HIV-1 entry. A U373-CD4/HeLa hybrid clone allows efficient HIV-1 replication. These results suggest that HeLa cells express a factor(s) that can complement the viral entry defect of U373-CD4 cells and is necessary for efficient CD4-mediated HIV-1 infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7690415      PMCID: PMC238014     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

Authors:  L A Lasky; G Nakamura; D H Smith; C Fennie; C Shimasaki; E Patzer; P Berman; T Gregory; D J Capon
Journal:  Cell       Date:  1987-09-11       Impact factor: 41.582

2.  Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity.

Authors:  J D Lifson; K M Hwang; P L Nara; B Fraser; M Padgett; N M Dunlop; L E Eiden
Journal:  Science       Date:  1988-08-05       Impact factor: 47.728

3.  Human immunodeficiency virus infection studied in CD4-expressing human-murine T-cell hybrids.

Authors:  M Tersmette; J J van Dongen; P R Clapham; R E de Goede; I L Wolvers-Tettero; A Geurts van Kessel; J G Huisman; R A Weiss; F Miedema
Journal:  Virology       Date:  1989-02       Impact factor: 3.616

4.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

5.  A new technique for the assay of infectivity of human adenovirus 5 DNA.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-04       Impact factor: 3.616

6.  Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus.

Authors:  W R Gallaher
Journal:  Cell       Date:  1987-07-31       Impact factor: 41.582

7.  Different requirements for membrane fusion mediated by the envelopes of human immunodeficiency virus types 1 and 2.

Authors:  T Dragic; M Alizon
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

8.  Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4.

Authors:  M A Skinner; A J Langlois; C B McDanal; J S McDougal; D P Bolognesi; T J Matthews
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

9.  Location and chemical synthesis of a binding site for HIV-1 on the CD4 protein.

Authors:  B A Jameson; P E Rao; L I Kong; B H Hahn; G M Shaw; L E Hood; S B Kent
Journal:  Science       Date:  1988-06-03       Impact factor: 47.728

10.  Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1.

Authors:  P S Linsley; J A Ledbetter; E Kinney-Thomas; S L Hu
Journal:  J Virol       Date:  1988-10       Impact factor: 5.103

View more
  52 in total

1.  Cooperation of the V1/V2 and V3 domains of human immunodeficiency virus type 1 gp120 for interaction with the CXCR4 receptor.

Authors:  B Labrosse; C Treboute; A Brelot; M Alizon
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Exploiting drug repositioning for discovery of a novel HIV combination therapy.

Authors:  Christine L Clouser; Steven E Patterson; Louis M Mansky
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

3.  Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.

Authors:  Christine L Clouser; Laurent Bonnac; Louis M Mansky; Steven E Patterson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

4.  Activity of a novel combined antiretroviral therapy of gemcitabine and decitabine in a mouse model for HIV-1.

Authors:  Christine L Clouser; Colleen M Holtz; Mary Mullett; Daune L Crankshaw; Jacquie E Briggs; M Gerard O'Sullivan; Steven E Patterson; Louis M Mansky
Journal:  Antimicrob Agents Chemother       Date:  2012-01-23       Impact factor: 5.191

5.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Langerhans cell tropism of human immunodeficiency virus type 1 subtype A through F isolates derived from different transmission groups.

Authors:  M T Dittmar; G Simmons; S Hibbitts; M O'Hare; S Louisirirotchanakul; S Beddows; J Weber; P R Clapham; R A Weiss
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Characterization of protein involvement in rabies virus binding to BHK-21 cells.

Authors:  J H Broughan; W H Wunner
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

Review 8.  Chemokine receptors and chemokines in HIV infection.

Authors:  A Garzino-Demo; A L DeVico; R C Gallo
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

9.  Exceptional fusogenicity of Chinese hamster ovary cells with murine retroviruses suggests roles for cellular factor(s) and receptor clusters in the membrane fusion process.

Authors:  D C Siess; S L Kozak; D Kabat
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  The cytomegalovirus-encoded chemokine receptor US28 can enhance cell-cell fusion mediated by different viral proteins.

Authors:  O Pleskoff; C Tréboute; M Alizon
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.